The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Evipan     5-(1-cyclohexenyl)-1,5- dimethyl-1,3...

Synonyms: Cyclonal, Cyclopan, Narcosan, Sombulex, Barbidorm, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hexenal


Psychiatry related information on Hexenal


High impact information on Hexenal


Chemical compound and disease context of Hexenal


Biological context of Hexenal


Anatomical context of Hexenal


Associations of Hexenal with other chemical compounds


Gene context of Hexenal


Analytical, diagnostic and therapeutic context of Hexenal

  • Hexobarbital sodium was administered by zero order intravenous (iv) infusion, and plasma concentrations were determined regularly by gas chromatography [19].
  • The elimination half-life of hexobarbital was 490 +/- 186 min in the hepatitis patients and 261 +/- 69 min in the control group [19].
  • The pharmacokinetics and urinary excretion of hexobarbital and its metabolites were, therefore, investigated following oral administration of a differentially labelled pseudoracemate that allowed determination of the fate of the individual enantiomers [36].
  • Tolerance was tested with an EEG threshold method where hexobarbital is infused intravenously to obtain a criterion of burst suppression [37].
  • The rate of metabolism of hexobarbital was determined in this system as the recirculating perfusion fluid was made hypoxic by exposure to either CO or lowered oxygen tension [15].


  1. Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. Joeres, R., Klinker, H., Heusler, H., Epping, J., Zilly, W., Richter, E. Hepatology (1988) [Pubmed]
  2. Hexobarbital disposition in compensated and decompensated cirrhosis of the liver. Zilly, W., Breimer, D.D., Richter, E. Clin. Pharmacol. Ther. (1978) [Pubmed]
  3. Depression of liver metabolism and induction of cytokine release by diphtheria and tetanus toxoids and pertussis vaccines: role of Bordetella pertussis cells in toxicity. Fantuzzi, G., Sironi, M., Delgado, R., Cantoni, L., Rizzardini, M., Carelli, M., Marsili, I., Ghiara, P., Ghezzi, P. Infect. Immun. (1994) [Pubmed]
  4. Comparison of the effect of carbon monoxide and of hypoxic hypoxia. I. In vivo metabolism, distribution and action of hexobarbital. Roth, R.A., Rubin, R.J. J. Pharmacol. Exp. Ther. (1976) [Pubmed]
  5. Hexobarbitone disposition at different stages of intensive care treatment. Rietbrock, I., Lazarus, G., Richter, E., Breimer, D.D. British journal of anaesthesia. (1981) [Pubmed]
  6. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. Chaki, S., Hirota, S., Funakoshi, T., Suzuki, Y., Suetake, S., Okubo, T., Ishii, T., Nakazato, A., Okuyama, S. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  7. The effect of chronic felbamate administration on anticonvulsant activity and hepatic drug-metabolizing enzymes in mice and rats. Swinyard, E.A., Woodhead, J.H., Franklin, M.R., Sofia, R.D., Kupferberg, H.J. Epilepsia (1987) [Pubmed]
  8. Antidiarrheal activity of alpha-2 adrenoceptor agonist SK&F 35886. Fondacaro, J.D., McCafferty, G.P., Kolpak, D.C., Smith, P.L. J. Pharmacol. Exp. Ther. (1989) [Pubmed]
  9. Activation of the anterior cingulate gyrus by 'Green Odor': a positron emission tomography study in the monkey. Sasabe, T., Kobayashi, M., Kondo, Y., Onoe, H., Matsubara, S., Yamamoto, S., Tsukada, H., Onoe, K., Watabe, H., Iida, H., Kogo, M., Sano, K., Hatanaka, A., Sawada, T., Watanabe, Y. Chem. Senses (2003) [Pubmed]
  10. Influence of alaproclate on antipyrine metabolite formation in man. Teunissen, M.W., Wahlén, A., Vinnars, E., Breimer, D.D. Eur. J. Clin. Pharmacol. (1984) [Pubmed]
  11. The effects of interleukin 2 and alpha-interferon administration on hepatic drug metabolism in mice. Ansher, S.S., Puri, R.K., Thompson, W.C., Habig, W.H. Cancer Res. (1992) [Pubmed]
  12. Gradients of O2 concentration in hepatocytes. Jones, D.P., Mason, H.S. J. Biol. Chem. (1978) [Pubmed]
  13. Variations in CYP74B2 (hydroperoxide lyase) gene expression differentially affect hexenal signaling in the Columbia and Landsberg erecta ecotypes of Arabidopsis. Duan, H., Huang, M.Y., Palacio, K., Schuler, M.A. Plant Physiol. (2005) [Pubmed]
  14. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2. Yasumori, T., Murayama, N., Yamazoe, Y., Kato, R. Clin. Pharmacol. Ther. (1990) [Pubmed]
  15. Comparison of the effect of carbon monoxide and of hypoxic hypoxia. II. Hexobarbital metabolism in the isolated, perfused rat liver. Roth, R.A., Rubin, R.J. J. Pharmacol. Exp. Ther. (1976) [Pubmed]
  16. Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach. Schellens, J.H., Janssens, A.R., van der Wart, J.H., van der Velde, E.A., Breimer, D.D. Eur. J. Clin. Invest. (1989) [Pubmed]
  17. Central alpha 2-adrenoceptors are highly stereoselective for dexmedetomidine, the dextro enantiomer of medetomidine. Savola, J.M., Virtanen, R. Eur. J. Pharmacol. (1991) [Pubmed]
  18. Protective effect of prostaglandins D2, E1 and I2 against cerebral hypoxia/anoxia in mice. Masuda, Y., Ochi, Y., Ochi, Y., Karasawa, T., Hatano, N., Kadokawa, T., Shimizu, M. Naunyn Schmiedebergs Arch. Pharmacol. (1986) [Pubmed]
  19. Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery. Breimer, D.D., Zilly, W., Richter, E. Clin. Pharmacol. Ther. (1975) [Pubmed]
  20. Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Benowitz, N.L., Nguyen, T.L., Jones, R.T., Herning, R.I., Bachman, J. Clin. Pharmacol. Ther. (1980) [Pubmed]
  21. Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney. Doi, K., Suzuki, Y., Nakao, A., Fujita, T., Noiri, E. Kidney Int. (2004) [Pubmed]
  22. The interaction between pilocarpine and hexobarbital in male rats. Wahlström, G. Psychopharmacology (Berl.) (1976) [Pubmed]
  23. Inhibitory effects of nilutamide, a new androgen receptor antagonist, on mouse and human liver cytochrome P-450. Babany, G., Tinel, M., Letteron, P., Freneaux, E., Berson, A., Larrey, D., Pessayre, D. Biochem. Pharmacol. (1989) [Pubmed]
  24. NADPH: cytochrome P-450 reductase in olfactory epithelium. Relevance to cytochrome P-450-dependent reactions. Reed, C.J., Lock, E.A., De Matteis, F. Biochem. J. (1986) [Pubmed]
  25. Barbital alteration of central nervous system sensitivity to hexobarbital in the rat. Schnell, R.C., Stoll, R.E., Prosser, T.D. Psychopharmacology (Berl.) (1976) [Pubmed]
  26. (E)-2-hexenal-induced DNA damage and formation of cyclic 1,N2-(1,3-propano)-2'-deoxyguanosine adducts in mammalian cells. Gölzer, P., Janzowski, C., Pool-Zobel, B.L., Eisenbrand, G. Chem. Res. Toxicol. (1996) [Pubmed]
  27. Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol. Robertson, D.W., Krushinski, J.H., Beedle, E.E., Leander, J.D., Wong, D.T., Rathbun, R.C. J. Med. Chem. (1986) [Pubmed]
  28. Growth hormone regulation of hepatic drug-metabolizing enzymes in the mouse. MacLeod, J.N., Shapiro, B.H. Biochem. Pharmacol. (1989) [Pubmed]
  29. Effect of barbiturates on polyphosphoinositide biosynthesis and protein kinase C activity in synaptosomes. Deshmukh, D.S., Kuizon, S., Chauhan, V.P., Brockerhoff, H. Neuropharmacology (1989) [Pubmed]
  30. Circadian rhythms in drug action and drug metabolism in the mouse. Holcslaw, T.L., Miya, T.S., Bousquet, W.S. J. Pharmacol. Exp. Ther. (1975) [Pubmed]
  31. Central effects of endothelin-1 (ET-1) and endothelin-3 (ET-3) in mice. Maslarova, J., Getova, D., Semkova, I., Nikolov, R. Methods and findings in experimental and clinical pharmacology. (1995) [Pubmed]
  32. Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor. Okuyama, S., Sakagawa, T., Chaki, S., Imagawa, Y., Ichiki, T., Inagami, T. Brain Res. (1999) [Pubmed]
  33. Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. Israel, B.C., Blouin, R.A., McIntyre, W., Shedlofsky, S.I. British journal of clinical pharmacology. (1993) [Pubmed]
  34. Effect of long-term multiple nifedipine administration on the antinociceptive activity of acetaminophen. Koleva, M., Dimova, S. Methods and findings in experimental and clinical pharmacology. (2001) [Pubmed]
  35. Cardiac toxic effects of trans-2-hexenal are mediated by induction of cardiomyocyte apoptotic pathways. Ping, P., Baines, C.P., Gu, Y., Prabhu, S.D., Zhang, J., Tsai, L.L., Cardwell, E., Zong, N.C., Vondriska, T.M., Korge, P., Bhatnagar, A., Wang, G.W. Cardiovasc. Toxicol. (2003) [Pubmed]
  36. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Adedoyin, A., Prakash, C., O'Shea, D., Blair, I.A., Wilkinson, G.R. Pharmacogenetics (1994) [Pubmed]
  37. The interaction between electrically induced convulsions and tolerance in the abstinence period after chronic barbital treatments in the rat. Wahlström, G. Psychopharmacology (Berl.) (1976) [Pubmed]
WikiGenes - Universities